ONCOLOGY.
DRUG INDUCED PERIPHERAL NEUROPATHY.
DE-RISK NEUROTOXICITY BEFORE THE CLINIC.
Benefits.
By measuring functional effects directly in human neurons, NETRI supports pharma teams select safer leads, optimize payloads and dosing strategies, and preserve efficacy while minimizing neuropathy-driven dose reductions or discontinuations.
Description.
Create a high throughput microscope-free platform to evaluate neurotoxicity as Drug Induced Peripheral Neuropathies (DIPN) for oncology drug development.
Readouts.
• MEA recordings.
• Digital Signatures.
• Imaging.
Advantages.
• Direct recording of neuronal response to compound pain challenge.
• Capacity to discriminate inflammatory, taxanes, platinum salts, vinca alcaloids, ADC.
EMETIC & NAUSEA RESPONSE.
DE-RISK EMETIC LIABILITY BEFORE THE CLINIC.
Benefits.
By measuring functional responses directly in human neurons relevant to emetic signaling, NETRI supports pharma teams to prioritize safer compounds, refine dosing and formulation strategies, and preserve treatment adherence while minimizing nausea- and vomiting-driven dose modifications.
Description.
Create a high throughput microscope-free platform to evaluate emetic response for oncology drug development and evaluate potential drug candidate combination to lower drug induced GI toxicity.
Readouts.
• MEA recordings.
• Digital Signatures.
• Imaging.
Advantages.
• Direct recording of neural-based emetic response.
• 5HT3 receptor expressed.
• Direct or indirect coupling with gut ephithelium.
ONCOLOGY.
POTENTIAL APPLICATIONS.
• Liver Toxicity: co-culture of hiPSC-derived sensory neurons and liver organoids to create an innervated skin NaaS platform.
• Cardiac Toxicity: co-culture of hiPSC-derived sensory neurons and hiPSC-derived cardiac muscle to create an innervated cardiac NaaS platform.
• Brain Toxicity: co-culture of hiPSC-derived sensory neurons and brain organoids to create an neurotoxicity NaaS platform.
• Glioblastoma Drug Efficacy: tri-culture of hiPSC-derived sensory neurons, primary endothelial cells and glioblastoma spheroids to create an innervated & vascularized glioblastoma NaaS platform.
• Drug Efficacy: co-culture of hiPSC-derived sensory neurons and tumoroids to create an innervated tumoroid NaaS platform.
OUR OFFERS.
Initialization.
Creation of NaaS biology platform and NaaS Model for a target application.
• In Your Lab: Develop your NaaS Model on your own terms.
• At NETRI: Let NETRI Develop your NaaS Model.
Upscaling.
Build up of Digital NaaS model through Training Library of 100s of reference compounds.
• Pre-Licensing: Test your molecules using your NaaS Model.
Screening & Drug Design.
Transfer of methodology, devices and predictive model capabilities to client.
• Licensing: Screen your molecules using an existing NaaS Model.
Regulatory Approval.
Extension of approved NaaS Model to multiple clients. Larger deals with CROs to handle volumes.
• Licensing & milestones.
